Open this publication in new window or tab >>Show others...
2025 (English)In: Frontiers in Oncology, E-ISSN 2234-943X, Vol. 15, article id 1451156Article in journal (Refereed) Published
Abstract [en]
Background: Glioblastoma (GBM) is the deadliest form of brain cancer, impacting both adults and children, marked by exceptionally high morbidity and mortality rates, even with current standard treatments such as surgery, radiation therapy, and chemotherapy. Therefore, there is a pressing need for new therapeutic strategies to improve survival and reduce treatment side effects. In this study, we investigated the effect of HSP90 inhibition in combination with radiotherapy in established and patient-derived glioblastoma cell lines.
Methods: Potential radiosensitizing effects of the HSP90 inhibitor Onalespib were studied in XTT and clonogenic survival assays as well as in tumor-mimicking multicellular spheroid models. Further, migration capacity and effects on protein expression were studied after exposure to Onalespib and radiation using Proximity Extension Assay analysis.
Results: HSP90 inhibition with Onalespib synergistically enhanced the radiosensitivity of glioblastoma cells grown in 2D and 3D models, resulting in increased cell death, reduced migration capacity and activation of the apoptotic signaling pathway. The proteomic analysis of glioblastoma cells treated with Onalespib, radiation, and their combination revealed significant alterations in protein expression profiles, involved in growth signaling, immune modulation pathways and angiogenesis. Moreover, the combination treatment indicated potential for enhancing cell cycle arrest and apoptosis, suggesting promising antitumor effects.
Conclusion: These findings demonstrate that HSP90 inhibition may be a promising strategy to enhance the efficacy of radiotherapy in the treatment of GBM, potent
Place, publisher, year, edition, pages
Frontiers Media S.A., 2025
Keywords
CNS tumors, synergy, heat shock protein, radiotherapy, combination therapy, proteomics, proximity extension assay
National Category
Basic Cancer Research
Identifiers
urn:nbn:se:uu:diva-553096 (URN)10.3389/fonc.2025.1451156 (DOI)001419221200001 ()39949745 (PubMedID)2-s2.0-85217744455 (Scopus ID)
Funder
Swedish Childhood Cancer Foundation, PR2023-0111Swedish Childhood Cancer Foundation, FT2023-0023Swedish Cancer Society, 21 0371 FESwedish Cancer Society, 22 2365 PjSwedish Cancer Society, 24 3787 PjÅke Wiberg FoundationErik, Karin och Gösta Selanders FoundationRegion Gavleborg
2025-03-232025-03-232025-03-24Bibliographically approved